<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114425</url>
  </required_header>
  <id_info>
    <org_study_id>382426005_1</org_study_id>
    <nct_id>NCT01114425</nct_id>
  </id_info>
  <brief_title>Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection</brief_title>
  <official_title>Etude Observationnelle Multicentrique Relative à la tolérance de ISENTRESS® + TRUVADA® Prescrite en Prophylaxie Post-exposition de Personnes récemment Soumises au Risque de Transmission d'Une Infection Par le VIH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective are to assess the nature and incidence of drug intolerance observed with a new
      antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1],
      prescribed in a setting of the treatment of individuals with recent exposure to a risk of
      transmission of HIV infection and to compare the results with those of previous studies
      conducted according to the same methodology, with other combinations of antiretrovirals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2010</start_date>
  <completion_date type="Actual">December 1, 2012</completion_date>
  <primary_completion_date type="Actual">August 1, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the nature and incidence of drug intolerance and to compare the results with those of previous studies conducted according to the same methodology, with other combinations of antiretrovirals.</measure>
    <time_frame>one year</time_frame>
    <description>Proportion of patients who stop the post-exposure treatment before the planned 28 days, owing to adverse reaction(s).
Proportion of patients reporting a post-exposure treatment-related side effect before the end of the treatment.</description>
  </primary_outcome>
  <enrollment type="Actual">149</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir (Isentress)</intervention_name>
    <description>raltegravir (Isentress) 400 mg bid</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  age 18 years or over

          -  consultation immediately following exposure to the risk of transmission of HIV
             infection (less than 48 hours, except in the case of rape when this period may be
             increased to a maximum of 120 hours)

          -  person capable of understanding the principle of the study and giving his/her informed
             consent

        Exclusion criteria

          -  subjects recently exposed to a risk of transmission of HIV infection in which the
             source patient is known to be infected with HIV and treated, and whose therapeutic
             history justifies the introduction of PET other than that proposed in this study

          -  subjects with a contraindication to the prescription of Truvada® and/or Isentress®
             (renal impairment, allergy, etc.)

          -  subjects previously treated with phenytoin, phenobarbital and rifampicin, since
             combination with raltegravir is contraindicated subjects known to be infected with
             hepatitis B virus, whether or not treated with lamivudine

          -  subjects refusing to take part in the study

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian RABAUD, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GERES</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <name_title>Christian RABAUD</name_title>
    <organization>GERES</organization>
  </responsible_party>
  <keyword>tolerability of post exposure to HIV infection prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

